苑东生物(688513) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 was ¥268,954,445.02, representing a year-on-year increase of 21.56%[6] - The net profit attributable to shareholders for Q1 2022 was ¥53,801,911.59, reflecting a growth of 24.28% compared to the same period last year[6] - The net profit after deducting non-recurring gains and losses was ¥41,879,428.99, with a year-on-year increase of 23.99%[6] - Basic and diluted earnings per share for Q1 2022 were both ¥0.45, up by 25.00% compared to the same period last year[9] - The company reported a total comprehensive income of ¥53,801,911.59 for Q1 2022, compared to ¥43,292,471.03 in Q1 2021, reflecting a growth of 24.3%[36] Cash Flow - The net cash flow from operating activities was ¥37,228,404.83, showing a significant increase of 32.50% year-on-year[6] - The company reported an increase in cash flow from operating activities primarily due to increased sales receipts[14] - Total cash inflow from operating activities amounted to 320,187,766.56, compared to 278,516,932.87, indicating an increase of about 15%[40] - Cash outflow from operating activities totaled 282,959,361.73, up from 250,420,942.31, representing an increase of around 13%[40] - The net cash flow from investing activities was -512,688,220.48, an improvement from -871,690,550.73 in the previous period[40] - The net cash flow from financing activities was 29,861,694.44, a significant improvement from -257,062.53 in the previous period[42] Assets and Liabilities - The total assets at the end of Q1 2022 amounted to ¥2,861,798,804.03, which is a 3.12% increase from the end of the previous year[9] - Total liabilities as of the end of the reporting period were ¥515,961,055.44, up from ¥483,601,755.82, reflecting a growth of 6.5%[34] - Total current liabilities increased from 432,458,963.97 RMB to 464,865,439.18 RMB, an increase of about 7.5%[28] - Total equity attributable to shareholders of the parent company was ¥2,345,837,748.59, an increase from ¥2,291,664,728.59, showing a growth of 2.4%[34] Shareholder Information - Total number of common stock shareholders at the end of the reporting period is 7,161[18] - The largest shareholder, Wang Ying, holds 41,900,000 shares, representing 34.89% of total shares[18] Research and Development - The company's R&D investment totaled ¥53,296,057.20, representing 19.82% of operating revenue, an increase of 0.93 percentage points year-on-year[9] - Research and development expenses for Q1 2022 amounted to ¥45,192,135.02, compared to ¥41,794,134.64 in Q1 2021, marking an increase of 8.6%[34] Inventory and Receivables - Accounts receivable decreased from 112,427,878.56 RMB to 94,449,255.47 RMB, a reduction of approximately 16%[25] - Inventory increased from 103,682,790.76 RMB to 121,148,058.49 RMB, an increase of about 16.8%[25] Non-Recurring Items - Non-recurring gains and losses for the period totaled ¥11,922,482.60, with government subsidies included amounting to ¥5,805,651.10[12]